📣 VC round data is live. Check it out!

Schott Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Schott Pharma and similar public comparables like Ansell, Haemonetics, Dentsply Sirona, Chengzhi and more.

Schott Pharma Overview

About Schott Pharma

Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.


Founded

1884

HQ

Germany

Employees

4.8K

Financials (LTM)

Revenue: $1B
EBITDA: $323M

EV

$3B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Schott Pharma Financials

Schott Pharma reported last 12-month revenue of $1B and EBITDA of $323M.

In the same LTM period, Schott Pharma generated $397M in gross profit, $323M in EBITDA, and $169M in net income.

Revenue (LTM)


Schott Pharma P&L

In the most recent fiscal year, Schott Pharma reported revenue of $1B and EBITDA of $337M.

Schott Pharma is profitable as of last fiscal year, with gross margin of 34%, EBITDA margin of 29%, and net margin of 15%.

See analyst estimates for Schott Pharma
LTMLast FY202320242025202620272028
Revenue$1B$1B$1B$1B$1B
Gross Profit$397M$390M$373M$381M$393M
Gross Margin34%34%35%34%34%
EBITDA$323M$337M$292M$315M$333M
EBITDA Margin27%29%27%28%29%
EBIT Margin19%20%19%20%19%
Net Profit$169M$172M$177M$175M$171M
Net Margin14%15%17%15%15%

Financial data powered by Morningstar, Inc.

Schott Pharma Stock Performance

Schott Pharma has current market cap of $3B, and enterprise value of $3B.

Market Cap Evolution


Schott Pharma's stock price is $17.52.

Schott Pharma share price increased by 0.4% in the last 30 days, and decreased by 46.7% in the last year.

Schott Pharma has an EPS (earnings per share) of $1.14.

See more trading valuation data for Schott Pharma
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$3B$3B0.0%0.4%0.4%-46.7%$1.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Schott Pharma Valuation Multiples

Schott Pharma trades at 2.3x EV/Revenue multiple, and 8.4x EV/EBITDA.

See NTM and 2027E valuation multiples for Schott Pharma

EV / Revenue (LTM)


Schott Pharma Financial Valuation Multiples

As of May 4, 2026, Schott Pharma has market cap of $3B and EV of $3B.

Schott Pharma has a P/E ratio of 15.6x.

LTMLast FY202320242025202620272028
EV/Revenue2.3x2.3x2.5x2.4x2.3x
EV/EBITDA8.4x8.0x9.3x8.6x8.1x
EV/EBIT12.0x11.6x13.1x12.2x12.3x
EV/Gross Profit6.8x6.9x7.3x7.1x6.9x
P/E15.6x15.3x14.9x15.1x15.5x
EV/FCF36.8x49.7x93.8x33.5x51.4x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Schott Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Schott Pharma Margins & Growth Rates

Schott Pharma grew revenue by 3% but EBITDA decreased by 5% in the last fiscal year.

In the most recent fiscal year, Schott Pharma reported gross margin of 34%, EBITDA margin of 29%, and net margin of 15%.

See estimated margins and future growth rates for Schott Pharma

Schott Pharma Margins

Last FY202420252026202720282029
Gross Margin34%34%34%34%
EBITDA Margin29%28%29%27%
EBIT Margin20%20%19%19%
Net Margin15%15%15%14%
FCF Margin5%7%5%7%

Schott Pharma Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth3%6%3%4%
Gross Profit Growth3%2%3%5%
EBITDA Growth(5%)8%6%(1%)
EBIT Growth(6%)8%(1%)3%
Net Profit Growth(3%)(2%)(2%)1%
FCF Growth59%180%(35%)70%

Data powered by FactSet, Inc. and Morningstar, Inc.

Schott Pharma Operational KPIs

Schott Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.

Schott Pharma's Rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Schott Pharma's Rule of X is 37% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Schott Pharma
LTMLast FY202320242025202620272028
Rule of 4033%31%———
Bessemer Rule of X40%37%———
Revenue per Employee—$0.2M———
Opex per Employee—$0.0M———
S&M Expenses to Revenue9%9%9%8%9%
G&A Expenses to Revenue5%5%5%5%5%
R&D Expenses to Revenue3%3%3%3%3%
Opex to Revenue—15%16%14%15%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Schott Pharma Competitors

Schott Pharma competitors include Ansell, Haemonetics, Dentsply Sirona, Chengzhi, Shandong Weigao Blood, Inner Mongolia Furui Medical Science, Kestra Medical Technologies, Shinva, Sopharma and BioLife Solutions.

Most Schott Pharma public comparables operate across Medical Supplies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Ansell1.6x1.6x9.2x8.4x
Haemonetics2.7x2.7x10.7x8.6x
Dentsply Sirona1.2x1.2x6.8x7.0x
Chengzhi1.6x—19.9x—
Shandong Weigao Blood3.2x3.2x14.8x14.8x
Inner Mongolia Furui Medical Science8.0x7.4x28.1x—
Kestra Medical Technologies17.2x11.0x(12.9x)(12.3x)
Shinva0.7x—7.8x—

This data is available for Pro users. Sign up to see all Schott Pharma competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Schott Pharma

When was Schott Pharma founded?Schott Pharma was founded in 1884.
Where is Schott Pharma headquartered?Schott Pharma is headquartered in Germany.
How many employees does Schott Pharma have?As of today, Schott Pharma has over 4K employees.
Is Schott Pharma publicly listed?Yes, Schott Pharma is a public company listed on Frankfurt Stock Exchange.
What is the stock symbol of Schott Pharma?Schott Pharma trades under 1SXP ticker.
When did Schott Pharma go public?Schott Pharma went public in 2023.
Who are competitors of Schott Pharma?Schott Pharma main competitors include Ansell, Haemonetics, Dentsply Sirona, Chengzhi, Shandong Weigao Blood, Inner Mongolia Furui Medical Science, Kestra Medical Technologies, Shinva, Sopharma, BioLife Solutions.
What is the current market cap of Schott Pharma?Schott Pharma's current market cap is $3B.
What is the current revenue of Schott Pharma?Schott Pharma's last 12 months revenue is $1B.
What is the current revenue growth of Schott Pharma?Schott Pharma revenue growth (NTM/LTM) is 5%.
What is the current EV/Revenue multiple of Schott Pharma?Current revenue multiple of Schott Pharma is 2.3x.
Is Schott Pharma profitable?Yes, Schott Pharma is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Schott Pharma?Schott Pharma's last 12 months EBITDA is $323M.
What is Schott Pharma's EBITDA margin?Schott Pharma's last 12 months EBITDA margin is 27%.
What is the current EV/EBITDA multiple of Schott Pharma?Current EBITDA multiple of Schott Pharma is 8.4x.
What is the current FCF of Schott Pharma?Schott Pharma's last 12 months FCF is $74M.
What is Schott Pharma's FCF margin?Schott Pharma's last 12 months FCF margin is 6%.
What is the current EV/FCF multiple of Schott Pharma?Current FCF multiple of Schott Pharma is 36.8x.
How many companies Schott Pharma has acquired to date?Schott Pharma hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Schott Pharma has invested to date?Schott Pharma hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Schott Pharma

Lists including Schott Pharma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial